1. Home >
  2. M&A >
  3. Divestiture >
  4. Japan >
  5. Harrow Acquires Santen - Branded Ophthalmic Portfolio

M&A Deal Summary

Harrow Acquires Santen - Branded Ophthalmic Portfolio

On July 18, 2023, Harrow acquired life science company Santen - Branded Ophthalmic Portfolio from Santen Pharmaceutical

Acquisition Highlights
  • This is Harrow’s 6th transaction in the Life Science sector.
  • This is Harrow’s 1st transaction in Japan.

M&A Deal Summary
Date 2023-07-18
Target Santen - Branded Ophthalmic Portfolio
Sector Life Science
Buyer(s) Harrow
Sellers(s) Santen Pharmaceutical
Deal Type Divestiture

Target

Santen - Branded Ophthalmic Portfolio

Osaka, Japan
Santen’s Branded Ophthalmic Portfolio Includes U.S. and Canadian commercial rights to Flarex, natacyn, tobradex st, verkazia, zerviate, and non-prescription brands freshkote and cationorm plus.

Search 205,528 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Harrow

Nashville, California, United States
Category Company
Founded 1998
Sector Life Science
Employees315
Revenue 130M USD (2023)
DESCRIPTION

Harrow is a developer, producer, and dispenser of novel compounded pharmaceuticals. The company's business primarily consists of four therapeutic segments including ophthalmology, urology, sinus and integrative medicine. Harrow was founded in 1998 and is based in Nashville, California.

DEAL STATS #
Overall 8 of 8
Sector (Life Science) 6 of 6
Type (Divestiture) 6 of 6
Country (Japan) 1 of 1
Year (2023) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-07-27 Sintetica - Patented Ophthalmic Surgical Drug Candidate

United States

Sintetica's Patented Ophthalmic Surgical Drug Candidate provides ocular surface anesthesia during ophthalmic interventions such as cataract surgery and intravitreal injections.

Buy -

Seller(S) 1

SELLER

Santen Pharmaceutical

Osaka, Japan
Category Company
Founded 1890
Sector Life Science
Employees3,744
Revenue 302.0B JPY (2024)
DESCRIPTION

Santen Pharmaceutical is an entity which engages in the research, development, manufacture, and marketing of ophthalmic and anti-rheumatic pharmaceuticals for the protection and enhancement of eyesight and health. Santen Pharmaceutical was founded in 1890 and is based in Osaka, Japan.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Japan) 1 of 1
Year (2023) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-16 Eyevance Pharmaceuticals

Fort Worth, Texas, United States

Eyevance Pharmaceuticals is committed to developing and commercializing innovative and impactful ophthalmic products that enable optimal vision, better quality of life, and address significant unmet medical needs. Eyevance Pharmaceuticals was founded in 2017 and is based in Fort Worth, Texas.

Buy -
Mergr

Product

Company

Legal